Cargando…

Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever

INTRODUCTION: This open-label pilot study aimed to investigate the efficacy of canakinumab in colchicine-resistant familial Mediterranean fever (FMF) patients. METHOD: Patients with one or more attacks in a month in the preceding 3 months despite colchicine were eligible to enter a 30-day run-in per...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gül, Ahmet, Ozdogan, Huri, Erer, Burak, Ugurlu, Serdal, Kasapcopur, Ozgur, Davis, Nicole, Sevgi, Serhan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559892/ https://www.ncbi.nlm.nih.gov/pubmed/26337145 http://dx.doi.org/10.1186/s13075-015-0765-4

Ejemplares similares

PW01-015 – Canakinumab in adults with colchicin resistant FMF
por: Gül, A, et al.
Publicado: (2013)

Quality of life changes with canakinumab therapy in adults with colchicine resistant FMF
por: Gul, A, et al.
Publicado: (2015)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine
por: Berdeli, Afig, et al.
Publicado: (2019)

Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever
por: Sener, Seher, et al.
Publicado: (2023)

Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial
por: Ozen, Seza, et al.
Publicado: (2020)

Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases
por: Yücel, Burcu Bozkaya, et al.
Publicado: (2021)

Development of focal segmental glomerulosclerosis in a patient with Familial Mediterranean Fever resistant to colchicine therapy under treatment with Canakinumab
por: Barut, K, et al.
Publicado: (2015)

Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever
por: Ugurlu, Serdal, et al.
Publicado: (2017)

Epidemiology of colchicine resistant Familial Mediterranean Fever disease (CrFMF) in Turkey
por: Turgay, S, et al.
Publicado: (2015)

Effectiveness of Colchicine or Canakinumab in Japanese Patients with Familial Mediterranean Fever: A Single-Center Study
por: Yoshida, Shuhei, et al.
Publicado: (2023)

Analysis of MEFV exon methylation and expression patterns in familial Mediterranean fever
por: Kirectepe, Asli K, et al.
Publicado: (2011)

PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013)

Canakinumab might be Protective against Severe COVID-19 for Patients with Autoinflammatory Disorders
por: Alkan, Arif, et al.
Publicado: (2022)

The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever
por: Sozeri, Betul, et al.
Publicado: (2016)

P01-011 – Colchicine compliance and amyloidosis
por: Ozdogan, H, et al.
Publicado: (2013)

OR7-005 – Canakinumab in childhood colchicine resistant FMF
por: Hashkes, PJ, et al.
Publicado: (2013)

The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever
por: Calligaris, Lorenzo, et al.
Publicado: (2007)

The Prevalence of Familial Mediterranean Fever and Behçet’s Disease: A Cross-Sectional Study
por: ALPARSLAN, Özgür, et al.
Publicado: (2020)

Anakinra treatment in patients with Familial Mediterranean Fever: a single-center experience
por: Ugurlu, S, et al.
Publicado: (2015)

Indications and efficacy of canakinumab in Familial Mediterranean Fever: report of three cases
por: Tsinti, Maria, et al.
Publicado: (2014)

Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment
por: Alpa, Mirella, et al.
Publicado: (2015)

A case of neurosarcoidosis with aggresive characteristics
por: Ugurlu, Serdal, et al.
Publicado: (2014)

The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
por: Kacar, Mark, et al.
Publicado: (2020)

Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine
por: Andreotti, Felicita, et al.
Publicado: (2021)

The IL-1 inhibitor Canakinumab for Familial Mediterranean Fever: the Greek experience in 12 patients
por: Laskari, K, et al.
Publicado: (2015)

Canakinumab: can it untie the Gordian knot of cardiovascular disease in patients with familial Mediterranean fever?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever
por: Karabulut, Yusuf, et al.
Publicado: (2022)

In Familial Mediterranean Fever, soluble TREM-1 plasma level is higher in case of amyloidosis
por: Ugurlu, Serdal, et al.
Publicado: (2020)

Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?
por: Omma, Ahmet, et al.
Publicado: (2021)

Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience
por: Kavrul Kayaalp, Gülşah, et al.
Publicado: (2023)

Can the Thiol/Disulfide Imbalance Be a Predictor of Colchicine Resistance in Familial Mediterranean Fever?
por: Omma, Ahmet, et al.
Publicado: (2017)

Improvement of Liver Involvement in Familial Mediterranean Fever After the Introduction of Canakinumab: A Case Report
por: Massaro, Maria Grazia, et al.
Publicado: (2020)

Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)
por: El Hasbani, Georges, et al.
Publicado: (2019)

Is Familial Mediterranean Fever a clinical diagnosis? Results of a field survey
por: Ozdogan, H, et al.
Publicado: (2015)

Economic impact of juvenile idiopathic arthritis and familial Mediterranean fever
por: Yucel, Ilker Kemal, et al.
Publicado: (2011)

Vitamin D levels in children with familial Mediterranean fever
por: Onur, Hatice, et al.
Publicado: (2016)

Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study
por: Esatoglu, Sinem Nihal, et al.
Publicado: (2017)

The patient experience of Colchicine Resistant-Familial Mediterranean Fever (cr-FMF)
por: Dandekar, P, et al.
Publicado: (2015)

IL1-blocking therapy in colchicine-resistant familial Mediterranean fever
por: Köhler, Birgit Maria, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fa20389fjgs8q9qjev98k2p5q4